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Background: Initiation of renal replacement therapy often results from a combination of 
kidney function deterioration and symptoms related to chronic kidney disease (CKD) 
progression. We investigated the association between kidney function decline and symptom 
development in patients with advanced CKD.  
Methods: In the EQUAL study, a European prospective cohort study, patients with advanced 
CKD of ≥65 years and a kidney function that dropped below 20 mL/min/1.73m2 were 
followed for one year. Linear mixed effects models were used to assess the association 
between kidney function decline and symptom development. The sum score for symptom 
number ranged from 0-33 and for overall symptom severity from 0-165, using the Dialysis 
Symptom Index. 
Results: At least one kidney function estimate with symptom number or overall symptom 
severity was available for 1109 and 1019 patients, respectively. The mean (95%-confidence 
interval) annual kidney function decline was 1.70 (1.32; 2.08) mL/min/1.73m2. Mean overall 
increase in symptom number and severity was 0.73 (0.28; 1.19) and 2.93 (1.34; 4.52) per 
year, respectively. A cross-sectional association between level of kidney function and 
symptoms was lacking. Furthermore, kidney function at cohort entry was not associated with 
symptom development. However, each mL/min/1.73m2 of annual kidney function decline 
was associated with an extra annual increase of 0.23 (0.07; 0.39) in the number of symptoms 
and 0.87 (0.35; 1.40) in overall symptom severity.  
Conclusions: A faster kidney function decline was associated with a steeper increase in both 
symptom number and severity. Considering the modest association, our results seem to 
suggest that repeated thorough assessment of symptom development during outpatient clinic 
visits, in addition to the monitoring of kidney function decline, is important for clinical 
decision-making. 
 








Patients with advanced stage chronic kidney disease (CKD) suffer from a wide range of 
symptoms. A growing body of evidence exists that CKD symptom burden is negatively 
correlated with health-related quality of life, and positively correlated with increased 
morbidity and mortality rates.[1, 2] Previous studies in people with stage 4-5 CKD show that 
poor mobility and weakness is experienced by more than two thirds of the patients, while 
poor appetite, pain, and itching is reported in about 60%.[3] In number of symptoms and 
severity, patients with CKD stage 5, managed conservatively, experienced a symptom burden 
similar to that of an advanced cancer population.[4] In general, the more prevalent symptoms 
were rated as more burdensome. However, the symptom pain was an exception, for which a 
disproportionately greater severity was reported.[4] Patients rate symptoms as one of the 
most important aspects of their kidney disease. One of the main reasons behind this is the 
severity of symptoms they experience.[5] Healthcare providers and patients also believe that 
symptoms should be one of the main focuses in CKD research.[6, 7]  
 
In a medical speciality like rheumatology decision-making often involves evaluation of 
symptom burden. As an example, the disease activity score, including symptoms, is used in 
decision-making regarding treatment initiation but also to evaluate the effect of treatment. 
Also in clinical nephrology, there is a fundamental knowledge that symptom evaluation is 
important. KDIGO guidelines recommend the initiation of RRT when symptoms are present, 
which is often although not invariably in the glomerular filtration rate (GFR) range between 5 
and 10 mL/min/m2.[8] From a clinical point of view, it could be expected that symptoms 
increase while kidney function deteriorates in patients with CKD. Surprisingly, however, 
evidence for this association is lacking. This is important, as in general there is a lack of 
association between kidney function and symptoms in cross-sectional studies.[3, 9, 10] The 
interplay between kidney function and symptoms remains unclear for the question when to 
start dialysis, as also illustrated by the Initiating Dialysis Early And Late (IDEAL) study, 
where patients were randomized to an early versus late start dialysis based upon estimated 
GFR (eGFR).[11] In this study physical symptoms played an important role in deciding if 
and when to initiate dialysis. A large proportion of patients randomized to the late starting 
group started earlier due to the presence of uremic symptoms. Thus, even though symptom 




the IDEAL study, the longitudinal association between change in kidney function and change 
in symptoms over time in patients with advanced CKD was never empirically investigated. 
 
To fill this gap, we aimed to study the association between kidney function decline and 
symptom development (i.e. symptom number and severity) over time in patients with 
advanced CKD. To replicate findings of existing literature, we also studied the cross-
sectional association between level of kidney function and symptoms at baseline, and to 
expand on this, we explored the association between the level of kidney function and 
symptom development. 
 
MARERIALS AND METHODS 
 
Study design and population  
The European Quality study on treatment in advanced chronic kidney disease (EQUAL 
study) is an ongoing prospective cohort study in patients with advanced CKD in Germany, 
Italy, Poland, Sweden, the United Kingdom, and the Netherlands. Approval was obtained 
from the medical ethical committees or corresponding institutional review boards (as 
appropriate) for all participating centers. All included patients gave their written informed 
consent. A full description of the EQUAL study has been published elsewhere.[12] In short, 
patients of ≥ 65 years were included with an incident estimated GFR (eGFR) drop to or 
below 20 mL/min/1.73m2 in the last six months. Patients were eligible when followed in a 
nephrology clinic, and were excluded when the eGFR drop was the result of an acute event or 
when a history of RRT (i.e. start of dialysis, or kidney transplantation) was present. Identified 
patients who met the eligibility criteria were consecutively approached. Patients were 
followed until kidney transplantation, death, moving to a center not participating in the 
EQUAL study, refusal for further participation, loss to follow-up or end of follow-up, 
whichever came first. For the current analyses, the follow-up time would end at the first 
occurrence of January 2018 or initiation of dialysis. Follow-up data at cohort entry, after six 
and twelve months of follow-up were used from patients recruited between March 2012 and 






Data collection and variable definitions 
In the EQUAL study patients are followed while receiving routine medical care as provided 
by the nephrology clinics. Data were collected and entered into a web-based clinical record 
form, developed for this specific purpose. Collected information included patients’ 
demographics, primary kidney disease, comorbid condition, ethnicity, medication, diet, 
physical examination and laboratory data. Physical examinations and collection of laboratory 
data were performed according to standard protocols and procedures following the routine 
care at the local participating sites. For the uniformity of the data, all participating centers 
completed a questionnaire capturing details on local laboratory methods, units of 
measurement and reference ranges. Subsequently, all data were recalculated into one uniform 
unit of choice. Kidney function was estimated according to the the 4-variable Modification of 
Diet in Renal Disease (MDRD) formula, taking into account age, sex, race, and serum 
creatinine.[13] See Supplemental Table S1 for detailed variable descriptions of primary 
kidney disease, educational level, diabetes mellitus and psychiatric disease.  
 
Data on lifestyle, marital status, and number and symptom severity were obtained through 
self-administered paper questionnaires. The list of symptoms (Supplemental Table S1) 
composed the original validated Dialysis Symptom Index (DSI) and complemented with 
items assessing the following symptoms: bleeding, loss of weight, and loss of strength.[14] 
These symptoms were added based on expert opinion of nephrologists collaborating on the 
EQUAL study. Furthermore, these symptoms were added at the bottom of the original DSI, 
thus did not influence the validity of the questionnaire. Patients responded about whether 
these symptoms were present in the past month. In total 33 symptoms were assessed, thus the 
total sum score for symptom number ranged from 0 to 33 symptoms. Additionally, for each 
symptom scored ‘present’, patients also rated symptom severity (how much burden they 
experienced) on a 5-point Likert scale ranging from 1 ‘not at all’ to 5 ‘very much’ 
burdensome. An overall symptom severity sum score ranging from 0 to 165 was generated, 
assigning a score of zero for symptoms that were absent.[15]  
 
Statistical analyses 
Baseline characteristics were presented as mean with standard deviation (SD) for normally 
distributed continuous variables, as median with interquartile range (IQR) for skewed 





For the main analyses, patients were included when at least one observation of both kidney 
function and symptom score was available. For the cross-sectional analysis, this applied at 
baseline and for the longitudinal analysis this applied for one observation in the 1 year of 
follow-up. Using linear mixed models only one observation is needed.[16] As a result, 
different patient numbers were used in the analyses (see Figure 1).  
 
We performed three main analyses. Firstly, linear regression analysis was performed to 
estimate the cross-sectional association between the level of eGFR at baseline and both the 
number and severity of symptoms at baseline to replicate findings of existing studies.  
 
Secondly, to investigate the association between the level of eGFR at baseline and the 
development in symptom number and severity over time, we used linear mixed effects 
models where patients were included as random intercepts and reported coefficient for the 
interaction between a continuous time and the level of eGFR at baseline.[16] 
 
Thirdly, the longitudinal association between eGFR decline and the development of symptom 
burden (either the number or severity of symptoms) over time was also estimated using linear 
mixed effects models. Regression coefficients for the additional change in symptom burden 
with one unit change in GFR were obtained as outcome by modelling trajectories of kidney 
function and symptoms simultaneously, thereby allowing within and between individual 
variations using the fixed and random effects model. Correlations and standard errors were 
estimated using the delta method.[17] 
 
Multiple imputation was used to minimize the risk of bias due to missing data.[18] Estimates 
and standard errors were calculated in each imputation set and pooled into one overall 
estimate and standard error according to Rubin’s rules.[19, 20] All confounders were 
assumed to be missing at random for which multiple imputation using a fully conditional 
specification with 10 repetitions is a valid technique and reduces bias compared to complete 
case analysis.[21, 22] Exposure and outcome variables were not imputed. In the multiple 
imputation model, we included all potential confounders, exposure and outcome variables. 
Non-normally distributed variables were transformed to approximate normality before 





All aforementioned analyses were adjusted for age, sex, ethnicity, country of residence, 
educational level, diabetes mellitus, cerebrovascular disease, myocardial infarction, 
hypertension, malignancy, psychiatric disease, body mass index (BMI), primary kidney 
disease, hemoglobin and proteinuria. For all analyses, the baseline confounders were used to 
adjust for confounding. In all aforementioned analyses, causal interpretations should be 
avoided.[23]  
 
For the purpose of illustration, mean trajectories of kidney function decline and development 
in number and severity of symptoms are plotted in figures using estimated marginal (EM) 
means obtained from linear mixed models with a random intercept for each patient, including 
time as categorical variable at baseline, after 6 and 12 months of follow-up.  
 
Sensitivity analyses 
Several preplanned sensitivity analyses were performed to assess the robustness of our main 
results. Analyses were repeated using eGFR based on the CKD-EPI equation instead of the 
MDRD. The cross-sectional association between kidney function and symptoms was also 
assessed after 6 and 12 months of follow-up, to allow for more variability in eGFR. 
Furthermore, the longitudinal analyses regarding the association between kidney function 
level and symptom development, and the association between the kidney function and 
symptom trajectories, were repeated using a two-stage approach in linear regression 
analysis.[24] First, we calculated the individual linear regression slopes of change in 
symptoms and kidney function per patient. In the second stage we correlated either the 
baseline eGFR or individual eGFR declines with the calculated individual slopes of either 
symptom number or overall symptom severity in a linear regression model. Finally, analyses 
were repeated for 13 uraemia- or disease-related symptoms (see Supplemental Table S1). 
These 13 symptoms are an adapted list of symptoms based on symptoms reported by the 
KDOQI guidelines and reported as most prevalent, frequent or severe in advanced kidney 
failure in literature.[3, 9, 15, 25-29]  
 
Analyses using linear mixed effects models were performed using SAS statistical package 
(version 9.4, SAS Institute, Cary, NC). All other analyses were performed using SPSS 23.0 









For the present analyses, a total of 1109 patients were included with at least one observation 
of symptom number and eGFR-MDRD, and 1019 patients were included with at least one 
observation of overall symptom severity and eGFR-MDRD. Median (IQR) follow-up time 
was 0.98 (0.64; 1.03) year. Baseline characteristics of both patient groups are presented in 
Table 1. The mean (SD) baseline eGFR was 18.9 (5.4) and 18.8 (5.3) mL/min/1.73m² in 
those patients with scores on either the number or overall severity of symptoms available, 
respectively. The median (IQR) age was 75.9 (70.5-80.8) and 75.7 (70.2-80.5) years for 
patients with symptom number and symptom severity scores available, respectively. The 
symptoms muscle soreness, difficulty concentrating, constipation and decreased appetite 
increased the most in terms of reported symptom presence over the one year follow-up period 
in our study population (see Supplemental Figure S1). The symptom severity increased the 
most for the symptoms difficulty in becoming sexually aroused, muscle soreness, difficulty 
concentrating and decreased interest (see Supplemental Figure S2). 
Baseline characteristics of patients with no observations of both eGFR-MDRD and overall 
symptom score during the first year of pre-dialysis care are shown in Supplemental Table 
S2. The baseline characteristics of included and excluded patients were comparable, though 
included patients comprised a slightly higher percentage of males than excluded patients. In 
the total EQUAL study population of 1651 patients, 205 patients initiated dialysis and 168 
patients dropped out during the first year of follow-up, and 239 patients did not yet reach the 
end of the first year follow-up period. 
 
Cross-sectional association of kidney function and symptoms at baseline 
At cohort entry, there was no cross-sectional association between the level of kidney function 
and number of symptoms (Table 2). Furthermore, we found no association between the level 
of kidney function and overall severity of symptoms at baseline. 
 
Association of kidney function at baseline and symptom development 
No association was found between the level of kidney function at cohort entry and 
development of symptoms over time. This applied to both the number and overall severity of 





Association of kidney function decline and symptom development 
The trajectories of kidney function decline and development of both the number and severity 
of symptoms over time are presented in Figure 2. The mean (95%-CI) annual kidney 
function decline was 1.63 (1.26; 2.00) mL/min/1.73m2. The mean (95%-CI) annual increase 
in number of symptoms was 0.73 (0.28; 1.19). Each unit (=1 mL/min/1.73m2) annual decline 
of kidney function was associated with an adjusted extra annual increase in number of 
symptoms with 0.23 (0.07; 0.39) point (Table 4). Besides, the mean increase in overall 
symptom severity was 2.93 (1.34; 4.52) points per year. Thereby, the symptoms difficulty 
concentrating, restless legs and decreased appetite increased most severely over time. Each 
unit of annual kidney function decline was associated with an adjusted extra annual increase 
in overall symptom severity with 0.87 (0.35, 1.40) point (Table 4). In other words, a faster 
kidney function decline was associated with a steeper increase in both the number of 
symptoms and the overall severity of symptoms per year in patients with advanced CKD. 
These numbers correspond to 32% and 30% of the mean annual increase of 0.23 in symptom 
number and 2.93 in overall symptom severity, respectively. Figure 3 illustrates the impact of 
one additional unit decline of kidney function on the development of overall symptom 
severity in an average patient.  
 
Sensitivity analyses 
Using the CKD-EPI instead of the MDRD equation yielded comparable results 
(Supplemental Tables S3-S5). After 6 and 12 months of follow-up, there was no cross-
sectional association between the level of kidney function and either the number or severity 
of symptoms (Supplemental Table S6). Repeating the longitudinal analyses with linear 
regression on individual slopes instead of linear mixed effects models yielded comparable 
results (Supplemental Tables S7-8). Also, repeating the analyses in individuals with 
complete questionnaire data on 13 disease-related symptoms did not materially change the 
results. Each unit decrease in kidney function decline was significantly associated with a 
more progressive increase in both number and overall severity of symptoms (Supplemental 
Tables S9-11). The association between kidney function decline and increase in overall 







In our study of older adults with advanced stage CKD, we found that a faster kidney function 
decline was associated with a steeper increase in the symptom burden over time in patients 
with advanced CKD. For each unit (=mL/min/1.73m2) annual decline of kidney function the 
increase in number and severity of symptoms steepens with 0.23 and 0.87 per year. This may 
seem modest, but is corresponding to approximately 30% of the mean annual increase in both 
symptom number and severity. We found neither a cross-sectional association in level of 
kidney function and symptoms nor an association between baseline kidney function and 
symptom development during the pre-dialysis phase. 
 
The symptom burden was substantial in our study population, which has been shown 
previously at baseline.[30] The symptom number at cohort entry is in concordance with 
observations in literature, reporting an average number of symptoms between 6 to 20 
symptoms in patients with CKD.[6, 31] Our symptom severity was somewhat higher than 
reported by Almutary et al.[25] Our mean annual increase in number of symptoms was 
similar to the increase of approximately half a symptom found in the 24 to 12 months prior to 
reaching the endpoint dialysis, transplantation or death in the study of de Goeij et al.[9] We 
found a mean (95% CI) increase in symptom severity of 2.93 (1.34; 4.52) per year. Our study 
is the first study that examined the increase in symptom severity over time in CKD patients. 
It is important to distinguish between symptom number and symptom severity in each 
individual patient.[4, 25] A higher symptom number does not necessarily mean that these 
patients experience a higher symptom severity. In a previous EQUAL study, we 
demonstrated that both symptom number and symptom severity influence the patient reported 
health related quality of life.[2] The contribution of symptoms to the quality of life variable 
was also larger than any other condition (e.g. age, comorbidity) investigated. 
 
The pathophysiological mechanisms underlying the onset of these symptoms and the 
interplay with kidney function are still not fully understood.[32] It is expected that with 
disease progression, the subjective manifestation of that condition (i.e. symptoms) will 
increase. This assumption also seems applicable to the symptom development in patients with 
advanced CKD: an increased number of symptoms and an increased symptom severity was 
experienced by patients with a faster kidney function decline. However, this relationship is 
not as straightforward as it appears. As in previous research that explored the relationship 
between kidney function and symptoms, we found no cross-sectional association between the 




found no cross-sectional association between eGFR and either symptom number or severity 
in conservatively managed patients with advanced CKD.[3] Furthermore, de Goeij et al 
showed that symptoms and eGFR-MDRD were not correlated in patients with CKD stage 4-5 
at four different time points during pre-dialysis care.[9] Apparently, the symptom score varies 
widely in patients with the same kidney function, considering the absence of these 
associations, and several possible explanations exist for these differences. First, the timing of 
symptom onset differs between patients, i.e. at different levels of kidney function.[9, 29] 
Second, literature suggests that, in addition to disease progression itself, social and 
psychological determinants play an important role in symptom development.[32] In particular 
psychological determinants are deemed to be relevant for patients’ experience of symptoms 
and their perception of symptom burden, for example: illness perceptions and coping 
strategies.[32, 35, 36] Thus, the lack of cross-sectional associations could be because patients 
with the same kidney function could report a variety of symptom number and severity due to 
differences in psychological factors.[33-38] In addition, CKD patients often have several 
comorbid conditions that would also contribute to the overall symptom burden. All of the 
above would dilute the true effect of symptoms caused by low kidney function in any cross-
sectional investigation. Studying the effect of kidney function loss and symptom development 
over time makes it easier to disentangle the association with kidney function on symptom 
burden per se.  
 
To our knowledge, this is the first study that examined the longitudinal association between 
change in kidney function and change in symptoms over time in patients with advanced 
CKD. In contrast to our findings, Brown et al found no association between categories 
(stable, improved or worsening) of symptoms and stable or decline in eGFR in elderly non-
dialysis patients with CKD stage 5.[39] However, we investigated the continuous change in 
kidney function and symptoms. The lack of an association in the study of Brown et al could 
be explained by the lack of adjustment for confounding and the loss of information by 
categorizing the change in symptoms. We extended these findings by showing the impact of a 
faster kidney function decline on the more progressive increase in symptoms over time in 
patients with advanced CKD, including adjustment for confounding. In addition, further 
research on this topic is warranted to unravel the mechanisms underlying the interplay 
between kidney function decline and symptom development, and the possible role of 




is important that healthcare professionals continue to focus on supporting patients in finding a 
way to deal with complaints and symptoms.[40]  
 
A major strength is that the EQUAL study is a large European multicentre prospective cohort 
study of incident patients with advanced CKD of at least 65 years old. This allowed us to 
examine the longitudinal association between kidney function decline and symptom 
development. The study design with a combination of limited exclusion criteria and the 
elimination of survivor bias by following patients from a common starting point (defined as 
incident eGFR ≤ 20 mL/min/1.73 m2), increases the generalizability of the obtained results to 
the clinical practice of pre-dialysis care for elderly patients. Limitations include the use of a 
single eGFR at each time point, possibly not reflecting the variability in eGFR. However, this 
is common in real-world clinical practice. Furthermore, the current analysis is restricted to 
the responders with at least one follow-up measurement. However, baseline characteristics of 
these responders are similar to characteristics of excluded patients. Furthermore, comparable 
results were obtained when confining the analyses to the 13 CKD-related symptoms or 
individuals with three measurements available of kidney function and symptoms. We should 
note that the advanced age of the cohort limits the generalizability to the whole non-dialysis 
patient population with CKD stage 4-5 and results should only be generalized to patients of at 
least 65 years old. We should acknowledge the possible limitations of the use of eGFR 
estimated based on serum creatinine, since serum creatinine excretion declines in elderly and 
is determined by person’s size and muscle mass. Furthermore, we assigned an equal weight to 
all symptoms to build a sum score based on the methodology of Abdel-Kader et al.15 
However, some symptoms could be more burdensome than others, although literature on this 
is scarce, therefore we were not able to assign different weights to each symptom. Finally, the 
DSI is the most commonly used symptom questionnaire, although developed and validated in 
dialysis patients. However, the DSI has been used in non-dialysis dependent patients 
before.[41, 42] The DSI is used in the EQUAL study, because the EQUAL study captures the 
pre-dialysis, transition, and dialysis phase.  
 
Although healthcare providers are aware of the symptom burden in patients with advanced 
CKD, and evaluation of symptoms are rated as important in the KDIGO guidelines,[8] the 
evidence behind this recommendation is “not graded”. This complicates anticipating 
treatment choices and advising when to initiate dialysis for symptom relief. Our results seem 




addition to the monitoring of kidney disease progression, is important throughout the pre-
dialysis period, for instance using Patient Reported Outcomes Measures (PROMs). Current 
research such as the SWIFT (symptom monitoring with feedback trial) in Australia/New 
Zealand and OPT-ePRO (OPTimising routine collection of electronic Patient-Reported 
Outcomes into disease registries) in the UK are investigating the effectiveness of routinely 
capturing PROMs in renal care. The underlying purpose is to improve symptom control, to 
reduce symptom number and severity, and to prepare for end stage kidney disease care. 
Developing better treatments to reduce symptoms of CKD is also suggested as a main 
research priority by patients.[7] Future research should focus on which CKD related 
symptoms possibly increase the most with kidney function deterioration. Additionally, 
uraemic signs and symptoms were rated as the most important factor guiding the timing of 
dialysis initiation in an international survey.[43] The important role of physical symptoms in 
deciding when to start dialysis, was also seen in the IDEAL study.[11] Furthermore, each 
additional sign or symptom has been shown to be associated with a higher odds for earlier 
dialysis initiation (odds ratio of 1.16 [95%-CI 1.06; 1.28] per symptom) in nursing home 
residents.[44] For future research it would be interesting to investigate whether the increase 
in symptom burden is associated with time to dialysis initiation or hospitalization, a longer 
follow-up would be needed in order to provide enough events. Ultimately, a clinical decision 
rule, including kidney function decline and symptom development, may be useful to decide 
what the optimal timing is for dialysis initiation. Of course, we have to keep in mind that 
nonspecific symptoms could be related to other comorbid conditions or illnesses precipitating 
early dialysis initiation among some providers.  
 
To conclude, we showed that a faster kidney function decline associates with a more 
progressive increase in both overall symptom number and severity in patients with advanced 
CKD. Considering the modest association, our results seem to suggest that repeated thorough 
assessment of symptom development during outpatient clinic visits, in addition to the 
monitoring of kidney function decline, is important for clinical decision making.  
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Table 1. Baseline characteristics in patients with at least two visits with eGFR-MDRD and overall symptom 
score available during first year of pre-dialysis 
 Symptom number and eGFR-
MDRD available for at least 
one visit during one year pre-
dialysis (N= 1109)a 
Symptom severity and eGFR-
MDRD available for at least 
one visit during one year pre-
dialysis (N= 1019)b 
Sex, male 764 (68.9) 698 (68.5) 
Age, years 75.9 (70.5-80.8) 75.7 (70.2-80.5) 
Ethnicity   
Caucasian 1087 (98.4) 1000 (98.4) 
Black 6 (0.5) 6 (0.6) 
Other 12 (1.1) 10 (1.0) 
Primary Kidney Disease   
Glomerular disease 106 (9.6) 99 (9.7) 
Tubulo-interstitial disease 95 (8.6) 89 (8.7) 
Diabetes Mellitus 214 (19.3) 187 (18.4) 
Hypertension 385 (34.7) 361 (35.4) 
Other/ unknown 309 (27.9) 283 (27.8) 
Educational level c   
No 27 (2.5) 24 (2.4) 
Low 308 (28.8) 266 (27.0) 
Intermediate 544 (50.9) 510 (51.8) 
High 154 (14.4) 151 (15.3) 
Other 36 (3.4) 34 (3.5) 
Marital status, married or living together 714 (66.0) 662 (66.6) 
Diabetes Mellitus, yes d 449 (41.3) 404 (40.4) 
Hypertension, yes e 991 (92.2) 919 (92.6) 
Cerebrovascular Disease, yes  168 (15.5) 152 (15.3) 
Myocardial Infarction, yes 202 (18.5) 185 (18.5) 
Malignancy, yes 228 (21.2) 210 (21.1) 
Psychiatric disease, yes 86 (7.9) 75 (7.5) 
Body Mass Index, kg/m² 28.2 (±5.3) 28.2 (±5.3) 
eGFR baseline, ml/min/1.73m²  18.9 (±5.4) 18.8 (±5.3) 
Serum albumin, g/L 37.6 (±5.9) 37.6 (±5.8) 
Hemoglobin, mmol/L 7.2 (±0.9) 7.2 (±0.9) 
Proteinuria, g/24h 1.5 (0.5-5.0) 1.5 (0.5-5.4) 
Values are given as frequency (percentage), mean (±SD) or median (IQR), as appropriate. 
a Missings: 0.4% ethnicity, 0.9% educational level, 2.5% marital status, 1.9% diabetes, 3.1% hypertension, 2.4% cerebrovascular disease, 
1.8% myocardial infarction, 2.8% malignancy, 2.3% psychiatric disease, 6.6% BMI, 9.8% albumin, 2.1% hemoglobin, 71.8% proteinuria. b 
Missings: 0.3% ethnicity, 2.5% marital status, 3.3% educational level, 1.9% diabetes, 2.6% hypertension, 2.3% cerebrovascular disease, 
1.8% myocardial infarction, 2.4% malignancy, 2.2% psychiatric disease, 6.8% BMI, 9.7% albumin, 2.1% hemoglobin, 71.9% proteinuria.  
c Defined as: low, no education or primary school only; intermediate, primary and secondary school; high, academic education. d Defined as 
the presence of diabetes mellitus as primary kidney disease or a history of diabetes mellitus, both type I and type II. e Defined as either the 






Table 2. Cross-sectional effect per unit lower eGFR-MDRD on symptom number and severity at baseline 
 Symptom number (N=980) Symptom severity (N=846) 
Unadjusted -0.01 (-0.08; 0.07) -0.06 (-0.34; 0.23) 
Adjusted a 0.004 (-0.07; 0.08) 0.06 (-0.22; 0.34) 
aAdjusted for: age, sex, ethnicity, country of residence, educational level, diabetes mellitus, cerebrovascular disease, myocardial infarction, 
hypertension, malignancy, psychiatric disease, BMI, primary kidney disease, hemoglobin, proteinuria at each specific time point (baseline, 6 




Table 3. Effect per unit lower eGFR-MDRD at baseline on annual change in symptom number and severity 
 Symptom number (N=1104) Symptom severity 
(N=1015) 
Mean annual increase (95%-CI) 0.76 (0.30; 1.21)* 3.00 (1.41; 4.59)* 
Extra increase per unita lower kidney function at baseline   
   Unadjusted  0.02 (-0.08; 0.11) -0.03 (-0.37; 0.30) 
   Adjusted b 0.08 (-0.01; 0.17) 0.21 (-0.13; 0.55) 
a 1 unit is 1 mL/min/1.73 m2  
b Adjusted for: age, sex, ethnicity, country of residence, educational level, diabetes mellitus, cerebrovascular disease, myocardial infarction, 
hypertension, malignancy, psychiatric disease, BMI, primary kidney disease, hemoglobin, proteinuria at baseline. 




Table 4. Effect per unit decline in eGFR-MDRD (per year) on annual change in symptom number and severity  
       Symptom number (N=1109) Symptom severity (N=1019) 
Mean annual increase (95%-CI) 0.73 (0.28; 1.19)* 2.93 (1.34; 4.52)* 
Extra increase per unita decline in kidney function  
   Unadjusted 0.24 (0.08; 0.40)* 0.88 (0.34; 1.41)* 
   Adjusted b  0.23 (0.07; 0.39)* 0.87 (0.35; 1.40)* 
a 1 unit is 1 mL/min/1.73 m2 decline per year  
b Adjusted for: age, sex, ethnicity, country of residence, educational level, diabetes mellitus, cerebrovascular disease, myocardial infarction, 
hypertension, malignancy, psychiatric disease, BMI, primary kidney disease, hemoglobin, proteinuria at baseline. 







Figure 1. Flowchart of patient inclusion for the present analyses, based on data availability.  
 
Figure 2. Overall mean (95% CI) trajectories, based on estimated marginal means, of kidney 
function decline and increase in number of symptoms (A) and mean (95% CI) kidney 
function decline and development of severity of symptoms over time in advanced CKD 
patients (B).  
 
  
Figure 3. Illustration of the adjusted mean annual slopes of kidney function (β1=1.70 
mL/min/1.73m2) and overall symptom severity (β4=2.93) in a patient with average covariate 
values (solid line). Furthermore, we show the impact of one additional mL/min/1.73 m2 
kidney function decline (β2=1.00 mL/min/1.73m
2) per year on the extra increase of the 
overall severity of symptoms over time (β3=0.87). The additional kidney function decline and 
resulting increase in symptom severity is represented with the dashed lines, this results in a 
total decline of kidney function of  β1+β2 (=2.70 mL/min/1.73m
2) and associates with a total 
increase in symptoms of β3+β4 (=3.80) per year.  
 
